MET and non-small cell lung carcinoma: Previous studies have demonstrated that multiple MET inhibitors showed promising efficacy for NSCLC patients with MET amplification or MET protein overexpression with an objective response rate of approximately 67% and 68% (IHC3+), respectively [8,9,10].